Posts

Welcome to the Fritsma Factor, please join our hemostasis discussions.

Second notice, forwarded on behalf of the North American Society on Thrombosis and Hemostasis:...
Jan 18, 2017 11:58am
A January, 2017 publication indicates that apixaban (Eliquis) yields fewer bleeds, less kidney...
Jan 16, 2017 8:33am
A colleague saw our January 10, 2017 entry describing T2MR, an emerging global hemostasis...
Jan 12, 2017 11:55am
Here is a Paul Riley, PhD follow up to Diane Treadway's discussion and follow-up comment comparing...
Jan 11, 2017 5:28pm
Jan 18, 2017 11:58am
Second notice, forwarded on behalf of the North American Society on Thrombosis and Hemostasis:  
0 Comments
Jan 16, 2017 8:33am
A January, 2017 publication indicates that apixaban (Eliquis) yields fewer bleeds, less kidney damage, and fewer strokes in patients with atrial fibrillation after transfemoral aortic valve replacement (TAVR) over the first 30 days of treatment. See Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J.
0 Comments
Jan 12, 2017 11:55am
A colleague saw our January 10, 2017 entry describing T2MR, an emerging global hemostasis methodology, and responded with information about sonic estimation of elasticity via resonance (SEER) sonorheometry, a non-contact technology that employs ultrasound to measure whole blood parameters similar to the viscoelasticity data
0 Comments
Jan 11, 2017 5:28pm
Here is a Paul Riley, PhD follow up to Diane Treadway's discussion and follow-up comment comparing the ISTAT INR to the central lab plasma-based PT/INR.
0 Comments